TrialBritish journal of cancer2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

N Colombo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.